Clinically, although phase II trials of FGF21 analogs (e.g., efruxifermin) demonstrate significant urate-lowering efficacy in metabolic syndrome cohorts,[46] our genetic evidence advocates for stratified intervention strategies. Here, FGF21 is linked to metabolic syndrome.